Ramaswamy's rare-disease offshoot Enzyvant poaches Alexion exec Rachelle Jacques to replace Alvin Shih at the helm
Alexion’s Rachelle Jacques is jumping ship to another rare disease biotech with a big promotion: CEO of Enzyvant Sciences, which was forged out of Vivek Ramaswamy’s prolific shop at Roivant back in 2016.
The company’s claim to fame is its lead drug — RVT-802 — for which a rolling marketing application has been initiated. The regenerative therapy, in-licensed from Duke University, is designed to reconstitute the immune system to treat primary immune deficiency resulting from congenital athymia, or a complete lack of a thymus. The FDA has laid out a red carpet for it by granting the experimental treatment breakthrough therapy designation and regenerative medicine advanced therapy (RMAT) status.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
